Long-Term Current Management of Enduring Obesity in Diabetes
- Author:
Chong Hwa KIM
1
Author Information
- Publication Type:Focused Issue
- From:Journal of Korean Diabetes 2020;21(1):21-26
- CountryRepublic of Korea
- Language:Korean
- Abstract: Obesity increases the risk of diabetes, hypertension, and cardiovascular diseases, ultimately contributing to mortality. The Korean Society for the Study of Obesity (KSSO) was established to improve the management of obesity through research and education; to that end, the Committee of Clinical Practice Guidelines of the KSSO reviews systemic evidence using expert panels to develop clinical guidelines. Weight-loss medications are effective adjuncts to diet, physical activity, and behavioral counseling for select Korean patients with type 2 diabetes and body mass index ≥ 25 kg/m2. Potential benefits must be weighed against the potential risks of these medications. If a patient's response to weight-loss medications is < 5% weight loss after 3 months or if there are significant safety or tolerability issues at any time, the medication should be discontinued and alternative medications or treatment approaches should be considered. Long-term medications for enduring obesity have traditionally fallen into two major categories, centrally-acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, I provide the definition of obesity in Korea and describe anti-obesity medications currently available for long-term treatment in diabetes.
